BioNTech aims to advance pipeline to the clinic with $325m investment

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags: Investment, Manufacturing, Biotech companies, CAR-T, Small molecule drugs, Antibody drug conjugates

BioNTech completed a $325m Series B financing rounds as the biotech looks to advance its therapeutics pipeline and manufacturing capabilities.

The clinical-stage biotechnology company​, focused on patient-specific immunotherapies, received $325m (€289.8m) in a Series B financing round. According to the company, this is one of the largest single private funding rounds for a European biotech.

According to Sean Marrett, CCO of BioNTech, funds from this financing round will be put toward the advancement of the company’s therapeutics pipeline and increasing its manufacturing infrastructure. He explained, "We have numerous programs in our pipeline and 7 different candidates already in 8 clinical trials. We anticipate additional programs to enter the clinic in the next 12 months." 

BioNTech’s pipeline​ includes individualized mRNA-based product candidates, chimeric antigen receptor (CAR)-T therapies, checkpoint immunomodulators, targeted cancer antibodies and small molecule drugs.

This funding follows a previous Series A financing in which the company received $270m in a round led by Redmile Group. This past financing enabled BioNTech to advance its seven product candidates in eight ongoing clinical trials, as well as establish a second good manufacturing practice (GMP) manufacturing license for production of its individualized neoantigen specific immunotherapies.

The company recently expanded its antibody platform, built with Genmab and MAB Discovery, after acquiring a Phase I/IIa program for the treatment of pancreatic cancer from MabVax Therapeutics.

Through the acquisition of MabVax’s antibody program, BioNTech established a US-based R&D facility in San Diego, California.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars